Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban.

Ponziani FR, De Candia E, De Cristofaro R et al.

Internal Medicine, Gastroenterology and Hepatology, Agostino Gemelli Hospital, Rome, Italy.

Liver international : official journal of the International Association for the Study of the Liver. Mar 2017.

De Gottardi et al.(1) have reported a safe use of direct oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis with or without liver cirrhosis. A few cases of portal vein thrombosis (PVT) resolution in cirrhotic patients after treatment with DOACs have been reported to date, whereas their efficacy in the prevention of PVT has not been investigated yet. We have recently observed a case of PVT occurred in a 81 year-old woman with cryptogenic liver cirrhosis, Child-Pugh score B8, under treatment with the DOAC rivaroxaban 20 mg daily for chronic atrial fibrillation. This article is protected by copyright. All rights reserved.